On February 4, 2022, Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. Wilson Sonsini Goodrich & Rosati is advising Acrellx on the transaction.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Arcellx, are expected to be approximately $123.8 million. In addition, Arcellx has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Arcellx. Arcellx’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 4, 2022, under the ticker symbol “ACLX.” The offering is expected to close on February 8, 2022, subject to the satisfaction of customary closing conditions. BofA Securities, SVB Leerink, Barclays, and William Blair are acting as joint book-running managers for the offering.

The Wilson Sonsini team advising Arcellx on the transaction includes:

Corporate:
Dan Koeppen
Megan Baier
Jennifer Fang
David Sharon
Amanda Creedon
Drew Kohlmeier
Tamara Labanowski

Technology Transactions – Biotech
Colin Bosch

Employee Benefits and Compensation
Scott McCall
Michael Klippert

FDA Regulatory, Healthcare, and Consumer Products
David Hoffmeister
Eva Yin

Delaware Corporate:
Ryan Greecher
James Griffin-Stanco
Emily Marco         

Tax:
Myra Sutanto Shen
Han Shen

Privacy and Cybersecurity:
Matthew Staples
Daniel Chen

For more information, please see Arcellx’s press release.